Sort   by:  
 Page size 
TranscriptomicsComparison of the gene expression profiles of carfilzomib-resistant derivatives versus parental human myeloma cell lines
KMS-11 and KMS-34 cells were exposed to stepwise increasing concentrations of carfilzomib over a period of 18 weeks: cells adapted to growth in 4 nM carfilzomib by 4 weeks, in 6 nM in another 6 weeks and in 12 nM after a further 8 weeks. The resulting cell cultures, denoted KMS-11/Cfz and KMS-34/Cfz...
ORGANISM(S): Homo sapiens 
2015-07-09 | E-GEOD-69078 | biostudies-arrayexpress
ProteomicsCarfilzomib-induced reticulocytosis in patients with multiple myeloma is caused by impaired terminal erythroid maturation
Proteasome inhibition constitutes a cornerstone of multiple myeloma (MM) treatment, with bortezomib, carfilzomib and ixazomib approved for clinical use. We observed a consistent and highly significant increase in the reticulocyte count during treatment with carfilzomib-based regimens in patients wi...
ORGANISM(S): Homo sapiens (Human) 
2020-02-20 | PXD014353 | Pride
Proteasome inhibitors Carfilzomib Multiple myeloma Erythropoiesis 
TranscriptomicsAMO-1 cell line after 8h of Ceritinib, Carfilzomib treatment and their combination
AMO-1 cell line after 8h of Ceritinib, Carfilzomib treatment and their combination. Cells were continuously treated for 8 h with 4uM Ceritinib and 5nM Carfilzomib. Cell pelets were stored at -80 degree and send on dry ice to BGI company.
ORGANISM(S): Homo sapiens 
2025-12-15 | E-MTAB-15466 | biostudies-arrayexpress
ProteomicsNovel carfilzomib-based combinations as potential therapeutic strategies for liposarcomas
Proteasome inhibitors, such as bortezomib and carfilzomib, have shown efficacy in anti-cancer therapy in hematological diseases but not in solid cancers. Here, we found that liposarcomas (LPS) are susceptible to proteasome inhibition, and identified drugs that synergize with carfilzomib, such as sel...
ORGANISM(S): Homo sapiens (Human) 
2020-09-28 | PXD020906 | Pride
Carfilzomib Silac Quantitative mass spectrometry Liposarcoma Proteasome 
GenomicsCarfilzomib inhibits the progression of hepatocellular cancer via upregulating GADD45a expression
Carfilzomib inhibits the progression of hepatocellular cancer via upregulating GADD45a expression
PRJNA1198859 | ENA
ProteomicsNovel carfilzomib-based combinations as potential therapeutic strategies for liposarcomas
Proteasome inhibitors, such as bortezomib and carfilzomib, have shown efficacy in anti-cancer therapy in hematological diseases but not in solid cancers. Here, we found that liposarcomas (LPS) are susceptible to proteasome inhibition, and identified drugs that synergize with carfilzomib, such as sel...
ORGANISM(S): Homo sapiens (Human) 
2020-09-28 | PXD021001 | Pride
Silac Proteasome Selinexor Quantitative proteomics Liposarcoma 
GenomicsPolyA RNA-seq from liposarcoma cells treated with Nutlin3R and/or Carfilzomib
PolyA RNA-seq from liposarcoma cells treated with Nutlin3R and/or Carfilzomib
PRJNA940486 | ENA
GenomicsAMO-1 cell line after 8h of Ceritinib, Carfilzomib treatment and their combination
AMO-1 cell line after 8h of Ceritinib, Carfilzomib treatment and their combination
PRJEB95817 | ENA
GenomicsWhole Exome Sequencing Analysis of Carfilzomib-Related Cardiotoxicity in Multiple Myeloma Patients
Whole Exome Sequencing Analysis of Carfilzomib-Related Cardiotoxicity in Multiple Myeloma Patients
PRJNA975677 | ENA
GenomicsWhole Exome Sequencing Analysis of Carfilzomib-Related Cardiotoxicity in Multiple Myeloma Patients
Whole Exome Sequencing Analysis of Carfilzomib-Related Cardiotoxicity in Multiple Myeloma Patients
PRJNA975678 | ENA
Sort   by:  
 Page size